PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Infect Dis. Author manuscript; available in PMC Apr 15, 2011.
Published in final edited form as:
PMCID: PMC2838976
NIHMSID: NIHMS170654
Relative Transmissibility of an R5 Clade C Simian-Human Immunodeficiency Virus Across Different Mucosae in Macaques Parallels the Relative Risks of Sexual HIV-1 Transmission Via Different Routes
Agnès L. Chenine,1,2 Nagadenahalli B. Siddappa,1,2 Victor G. Kramer,1 Gaia Sciaranghella,1,2 Robert A. Rasmussen,1,2 Sandra J. Lee,3 Michael Santosuosso,2,4 Mark C. Poznansky,2,4 Vijayakumar Velu,5 Rama R. Amara,5 Chris Souder,5 Daniel C. Anderson,5 François Villinger,5 James G. Else,5 Francis J. Novembre,5 Elizabeth Strobert,5 Shawn P. O’Neil,2,6 W. Evan Secor,7 and Ruth M. Ruprecht1,2
1Dana-Farber Cancer Institute, Massachusetts General Hospital, Boston, MA, USA.
2Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
3Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Massachusetts General Hospital, Boston, MA, USA.
4Partners AIDS Research Center and Infectious Diseases Medicine, Massachusetts General Hospital, Boston, MA, USA.
5Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
6New England Primate Research Center, Southborough, MA, USA.
7Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
A-L. C: Current address: HIV Research Program, Henry M. Jackson Foundation, Rockville, MD, USA.
Background
Worldwide, ~90% of all HIV transmissions occur mucosally; almost all involve R5 strains. Risks of sexual HIV acquisition are highest for rectal, followed by vaginal and then oral exposures.
Methods
Mucosal lacerations may affect the rank-order of susceptibility to HIV but cannot be assessed in humans. We measured relative virus transmissibility across intact mucosae in macaques using a single stock of SHIV-1157ipd3N4, a simian-human immunodeficiency virus encoding a primary R5 HIV clade C env (SHIV-C).
Results
The penetrability of rhesus macaque mucosae differed significantly, with rectal challenge requiring the least virus, followed by the vaginal and then oral routes. These findings imply that intrinsic mucosal properties are responsible for the differential mucosal permeability. The latter paralleled the rank-order reported for humans, with relative risk estimates within the range of epidemiologic human studies. To test whether inflammation facilitates virus transmission – as predicted from human studies – we established a macaque model of localized buccal inflammation. Systemic infection occurred across inflamed, but not normal buccal mucosa.
Conclusion
Our primate data recapitulate virus transmission risks observed in humans, thus establishing R5 SHIV-1157ipd3N4 in macaques as a robust model system to study cofactors involved in human mucosal HIV transmission and its prevention.
Most HIV-1 infections worldwide occur mucosally, involving unprotected sexual acts or mother-to-child transmission. Viruses with exclusive R5 tropism cause most mucosal HIV-1 acquisitions, which occur rectally, vaginally, and orally (reviewed in [1-6]). Oral transmission is seen in breast-feeding infants and has been described for oral-genital contact in adults (reviewed in [1, 7]). Epidemiological studies, including studies of serodiscordant couples, have yielded relative risk estimates for the three routes and identified unprotected rectal intercourse as the riskiest behavior, followed by vaginal exposure and finally, orogenital contact [3, 8-11]. Multiple cofactors have been linked to HIV-1 transmission, including coinfections and mucosal tears, but it is difficult to measure the impact of these factors on the rank-order of mucosal HIV-1 acquisition in humans. Thus, to evaluate relative virus transmissibility across intact mucosal surfaces, we tested different exposure routes in nonhuman primates free of known pathogens.
Mucosal lentiviral transmission studies have been performed rectally, vaginally, and orally in macaques, which are susceptible to simian immunodeficiency virus (SIV) and chimeric simian-human immunodeficiency virus (SHIV) strains encoding HIV-1 env [7, 12-19]. Previously, we compared the relative transmissibility of SIV, using an identical SIVDelta B670 stock, by the intravenous, intrarectal and oral routes in macaques that underwent non-traumatic mucosal inoculations [14]. Unexpectedly, oral challenge required 60x less virus to achieve systemic infection compared to intrarectal challenge. This puzzling finding contradicted the relative risks of HIV-1 acquisition through anogenital versus orogenital sexual exposure in humans. Multiple factors may account for the discrepancy between the primate model data and human epidemiological observations, including the fact that SIVDeltaB670 is dualtropic. Because almost all mucosal HIV-1 infections are caused by R5 viruses, we sought to address the question of relative lentiviral transmissibility with a clade C SHIV (SHIV-C) that encodes an HIV-1 envelope with exclusive CCR5 tropism.
Most SHIVs encode env of HIV-1 clade B, which causes <10% of all global infections. In contrast, HIV-1 clade C (HIV-C) causes 56% of all infections worldwide and predominates in Sub-Saharan Africa and India (www.unaids.org). Here, we report the relative mucosal transmissibility and pathogenesis of an R5 SHIV-C, SHIV-1157ipd3N4 [20, 21].
Rhesus monkeys
Indian- and Chinese-origin macaques were used according to National Institutes of Health guidelines on the care and use of laboratory animals at the Yerkes National Primate Research Center (Emory University) and the Centers for Disease Control and Prevention (CDC), both fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International. Animal experiments were approved by Institutional Animal Care and Use Committees of Emory University, CDC, and DFCI. All procedures were performed on anesthetized macaques. Chinese-origin macaques used for intrarectal titration served as normal controls elsewhere [22].
Major histocompatibility complex (MHC) class I typing of macaques
Indian-origin macaques were Mamu-A*01-negative except RBo-6, RDl-9, and RQv-8 (vaginal titration), and RAf-10 (oral titration). MHC alleles for Chinese-origin macaques were unavailable.
Virus stock
The exclusive R5-tropic SHIV-1157ipd3N4 [20] was grown in pooled PBMC from two Indian macaques (p27, 227 ng/ml; 50% tissue culture infectious doses (TCID50) by TZM-bl cell assay [23], 4×106/ml).
Mucosal SHIV-1157ipd3N4 challenges
All inoculations were performed atraumatically; anesthetized macaques received various virus stock dilutions in a total volume of 3 ml (oral route) or 1 ml (intrarectal and intravaginal routes). For details, see Supplemental Online Materials. For standard oral inoculations, virus was applied to the back of the tongue, in contrast to challenge via buccal mucosa.
Plasma viral RNA levels
RNA was isolated with QiaAmp Viral RNA Mini-Kits (Qiagen, Valencia, CA); viral RNA levels were measured by quantitative RT-PCR (assay sensitivity, 50 copies/ml) [24].
Staining of cells from blood, lymph node (LN), and rectal biopsies
PBMC and LN cells were isolated using standard procedures; lymphocytes from rectal pinch biopsies were obtained by collagenase digestion followed by Percoll gradient centrifugation; ~1×106 lymphocytes were surface stained as described [20, 25].
Induction of local inflammation in buccal mucosa
A circle was drawn inside the right cheek of anesthetized macaques with surgical pen/template. Multiple 30-μl aliquots of 10% acetic acid were administered submucosally into the circle via microsyringe. To study the inflammation time course, four macaques were given 10% acetic acid (6×30 μl submucosally) into the circle. Biopsies were taken from one of the macaques on d0, d3, d4, or d7. For details, see Supplemental Online Materials.
SHIV-1157ipd3N4 challenge across normal or inflamed buccal mucosa
Four macaques received 6×30 μl of 10% acetic acid. On d4 after this, with the macaque lying with the right cheek down, a plastic ring was placed over the inked circle, into which virus was placed in a total volume of 300 μl, left for 5 min, then adsorbed with gauze and the ring was removed. Four naïve macaques were challenged likewise.
Immunohistochemistry
CD4+ cells were identified in formalin-fixed, paraffinembedded buccal mucosa sections using reagents from Vector Labs (Burlingame, CA): anti-human CD4 mAb (clone 1F6), biotinylated horse anti-mouse IgG, immunoperoxidase kits (Vectastain ABC Elite), and the chromogenic substrate 3,3′-diaminobenzidine [26].
Statistical analyses
The distribution of 50% animal infectious dose (AID50) values for all titrations was determined by the Spouge method [27], which uses log-transformed data and provides AID50 means/standard deviations. To assess associations between AID50 values and the different titration groups, two-sample t-tests were performed using means/standard deviations estimated according to Spouge. Viral RNA loads and flow cytometry data were evaluated using Prism (GraphPad Software, San Diego, CA) and Mann-Whitney tests.
SHIV-C titrations by different mucosal routes
Indian-origin macaques were given different dilutions of the identical SHIV-1157ipd3N4 stock orally (n=6), intravaginally (n=7) and intrarectally (n=6) and followed prospectively for plasma viral RNA loads; systemic infection was confirmed by Western blots at week 12. Although macaques were exposed to different viral doses, peak viremia levels were similar for all three routes of transmission, and no differences were seen in viral setpoints (Figure 1). For single-virus challenges, including those reported here, a lack of correlation between inoculum size, peak viremia, viral set points, and disease progression has been described [28, 29].
Figure 1
Figure 1
Viremia in Indian-origin rhesus inoculated with SHIV-1157ipd3N4 orally (A), vaginally (B), or intrarectally (C); (D) viremia in Chinese-origin rhesus inoculated intrarectally. Animals were exposed to different dilutions of the same stock. *RQ3911 had (more ...)
Determination of SHIV-1157ipd3N4 minimal infectious dose and AID50
The minimal infectious dose needed to obtain systemic infection was lowest for the intrarectal route (dilution 1:100), followed by the intravaginal (1:20) and finally, the oral routes (1:10) (Table 1). The statistical method of Spouge [27] was used to determine AID50 values for each route and yielded again the rank-order: rectal (5.5 μl)<vaginal (23.9 μl)<oral (181 μl) (Table 1). Thus, without mucosal lesions, the rectal route was most permissive, followed by the intravaginal, and finally, the oral route. The relative rank-order for mucosal R5 SHIV-C transmission in our primate model paralleled that observed for humans sexually exposed to HIV-1 via different risk behaviors.
Table 1
Table 1
Relative mucosal permeability to SHIV-C in rhesus monkeys and relative risks of sexual HIV acquisition
Relative mucosal permeability and sexual transmission
We reasoned that SHIV-C AID50 values, expressed as volumes of undiluted virus stock required to achieve systemic infection in half of all exposed macaques, are indirectly proportional to the ease with which virus crossed a given mucosal surface. Thus, the AID50 values for the oral (181 μl), vaginal (23.9 μl) and the rectal routes (5.5 μl) were converted to 1/AID50 and normalized according to their ratios, after assigning a value of 1 to the oral route (Table 1). The ratios of 1:7.6:33 (oral:vaginal:rectal exposure) reflect the relative mucosal permeability to our R5 SHIV in experimental settings, where mucosal trauma was avoided.
Next, we searched the literature for estimates of relative risks of HIV-1 acquisition for different routes of sexual transmission (unprotected oral sex, male-to-female transmission by vaginal intercourse, rectal intercourse), which are generally expressed as numbers of new HIV infections per 1,000 exposures [9-11, 30-35] (reviewed in [1-3, 36]). Given the complexity of human sexual practices, the possible influence of cofactors (including coinfections and mucosal tears), the inability to determine exact times of HIV exposure and inoculum size, it is not surprising that these estimates vary widely. Per 1,000 unprotected exposures, the number of new HIV-1 infections ranged from 3.3 to 50 for rectal exposure, 0.5 to 5 for vaginal exposure [9-11, 30-34] (reviewed in [2, 3]), and 0.4 for orogenital exposure [35] (reviewed in [1, 36]). As we sought to compare the relative risks of HIV-1 acquisition by various mucosal routes with our primate data, we again set the value for oral-genital HIV-1 exposure at 1. Proportionally, the ratios of oral:vaginal:rectal HIV-1 acquisition were 1:(1.3 to 12):(8.3 to 125)(Table 1). Remarkably, the ratios measured experimentally for relative mucosal permeability by our non-traumatic mucosal R5 SHIV inoculations in macaques fell within the ranges extrapolated from epidemiological studies in HIV-1-exposed humans.
The susceptibility of Chinese-origin macaques to intrarectal SHIV-C
Because Indian-origin rhesus macaques have been widely used for AIDS research, their supply has become limited. Chinese-origin rhesus are more readily available and have been utilized for SIVmac infection [37, 38]. To evaluate whether Chinese-origin macaques would yield similar results to Indian macaques, we compared the susceptibility of the two subsets to rectal SHIV-1157ipd3N4 exposure.
Nine Chinese-origin macaques were used for intrarectal titration; the minimal infectious dose was higher compared to Indian macaques (Figure 1C,D). The AID50 extrapolated according to Spouge [27] for Chinese macaques was 4.5x higher than that for Indian macaques (P=0.015; two-sided t-test), which probably reflects the prior SHIV-1157ipd3N4 adaptation in Indian macaques [20, 21]. However, both infected macaque subsets showed similar peak viral RNA loads (7.1×106 for Indian vs. 3.8×106 copies/ml for Chinese macaques; P=0.22; Mann-Whitney test). Interestingly, only 40% of the infected Indian macaques were still viremic at week 12, in contrast to all infected Chinese macaques, in which viremia was significantly higher compared to their Indian counterparts (P=0.008; Mann-Whitney test; Figure 1D). Together, these data indicate that intrarectal SHIV-1157ipd3N4 transmission is reproducible in both macaque subsets. Furthermore, mucosal SHIV-1157ipd3N4 challenge and patterns of viremia in Chinese macaques indicate that this subspecies is well suited for lentiviral pathogenesis and vaccine development studies.
Establishment of a macaque model for local mucosal inflammation
To test whether our SHIV-C mucosal challenge model would yield an increased rate of transmission in the presence of inflammation, as would be expected from human epidemiologic studies, we induced localized inflammation in buccal mucosa with acetic acid and adapted the protocol developed for hamsters [39] to macaques.
The course of oral inflammation was followed daily for 2 weeks with clinical exams and photography (Figure 2). On different days, one macaque underwent punch biopsy; an untreated macaque was used as control. Hematoxylin/eosin-stained sections of oral biopsy specimens revealed mild edema and keratinocyte necrosis in stratified squamous epithelium lining the buccal mucosa, first noticeable on d4 and followed by hemorrhage and occasional fibrinoid dermal vessel necrosis on d7. No mucosal ulcerations and minimal inflammatory cell infiltration in the lamina propria were seen. Immunohistochemistry (Figure 3A-D) showed CD4+ cell infiltration, first apparent in perivascular sites on d3 post-acetic acid and progressing to diffuse infiltration throughout the lamina propria (Figure 3D). Physical exams and immunohistochemistry established d4 post-acetic acid injection as optimal time to assess whether localized inflammation – without frank mucosal breakdown – would facilitate virus transmission.
Figure 2
Figure 2
Induction of local inflammation of buccal mucosa (black rectangle) 4 days after acetic acid administration.
Figure 3
Figure 3
Immunohistochemistry for CD4 in buccal biopsies collected before (A) and after exposure to acetic acid (C-D). (A) Arrowhead, basement membrane separating epithelium (Epi) from lamina propria (LP). Individual (arrow) and small groups of CD4+ cells (brown) (more ...)
SHIV-C transmission across inflamed versus normal buccal mucosa
Macaques (n=8) were entered pair-wise: one with inflammation and one control. The macaque exposed to acetic acid was monitored daily for signs of inflammation. Once the latter was confirmed, both macaques were exposed to SHIV-1157ipd3N4 using either undiluted virus (3 pairs) or virus diluted 1:10 (1 pair) in a total volume of 300 μl. To prevent virus dispersion throughout the oral cavity, a small plastic ring was placed over the site of buccal inflammation or normal buccal mucosa and virus was applied inside the ring. This procedure restricts virus exposure to buccal mucosa, in contrast to our standard oral inoculation protocol. Two out of four macaques with buccal inflammation given undiluted virus were systemically infected, whereas all animals given diluted virus and controls remained negative, suggesting that healthy buccal mucosa is relatively impervious to SHIV-C transmission. The increased presence of viral target cells probably accounts for enhanced transmission across inflamed mucosa. We conclude that our SHIV-C model recapitulates the increased mucosal HIV transmission noted in humans with oral lesions [40, 41].
CD4+ lymphocyte depletion during acute SHIV-C infection
To assess SHIV-1157ipd3N4 pathogenicity, blood, LN and rectal biopsies were performed on Indian macaques at weeks 5 and 12 post-inoculation. Significant depletion of CD4+ T cells was noted in all three compartments in infected compared to uninfected macaques (n=8; P<0.05; Mann-Whitney test; Figure 4A-C). Similar degrees of gut CD4 T-cell depletion have been noted during acute infection with another R5 SHIV-C [25].
Figure 4
Figure 4
SHIV-1157ipd3N4 pathogenicity. (A-C) Percentage of CD4+ T cells (vs total T cells) of macaques with systemic SHIV-1157ipd3N4 infection or naïve controls; LN and rectal biopsies were performed at weeks 5 and 12; P<0.05 for both comparisons (more ...)
Progression of mucosally infected macaques to AIDS
During acute infection (within 12 weeks post-inoculation), gradual depletion of peripheral blood CD4+ memory T cells (assessed by CD4+CD29+ double-staining) was noted in two of the 21 systemically infected macaques in different titrations. Rapid disease progression did not occur. Out of five chronically infected Indian-origin macaques followed longterm to estimate SHIV-1157ipd3N4 pathogenicity, monkey RJs-10 developed AIDS at week 102, and one of five Chinese-origin macaques (RQ3911) at week 142 (Figure 4D,E). This animal also had severe thrombocytopenia. At necropsy 20 weeks later, streptococcal endocarditis and multiple focal hemorrhages were found. Two additional Chinese macaques had <500 CD4 T cells/μl, indicating progressive disease in three out of the five macaques. These pilot data suggest that SHIV-1157ipd3N4 is pathogenic in macaques with gradual disease progression, similar to HIV-1 in humans.
Our primate model data show: 1) SHIV-1157ipd3N4 is transmissible across all mucosal routes tested; 2) relative mucosal permeability was rectal>vaginal>oral, reflecting the risk order of sexual HIV acquisition among humans; 3) SHIV-1157ipd3N4 was transmissible across inflamed, but not normal buccal mucosa; and 4) SHIV-1157ipd3N4 showed signs of pathogenicity during acute infection and caused gradual progression to AIDS.
Our R5 SHIV-C mucosal transmission data contrast our earlier rhesus macaque study involving SIVDeltaB670, where the oral route was 60x more permissive than the rectal route [14], an unexpected result we ascribe to expanded SIVDeltaB670 coreceptor usage. In contrast, SHIV-1157ipd3N4 solely uses CCR5. As such, this R5 SHIV-C better reflects HIV-1 strains typically transmitted sexually among humans. Indeed, the permeability of intact macaque mucosae to SHIV-1157ipd3N4 was rectal>vaginal>oral, a pattern that not only followed the rank-order but also fell within the ranges extrapolated from HIV-1-exposed humans [9-11, 30-35] (reviewed in [1-3, 36]). These findings attest to the biological relevance of our new R5 SHIV-C/primate model.
Estimating the relative risks of HIV-1 acquisition due to exclusive orogenital contact among humans is difficult, and not surprisingly, a recent survey [1] was unable to perform a meta-analysis of earlier reports. The complexity of human sexual practices makes it difficult to study sufficiently large numbers of individuals whose only risk of sexual HIV-1 acquisition is orogenital exposure. Assessing the route of HIV-1 acquisition depends on recall, which may be inaccurate and underestimate the influence of sexual practices known to be high-risk, such as lack of condom use for rectal intercourse. Several human cohort studies reported no cases of HIV-1 seroconversion attributable solely to orogenital contact (reviewed in [1]); the only quantitative risk-per exposure estimate we could locate in the literature was a risk of 0.4 per 1000 exposures [35]. Consequently, human epidemiological studies would have to enroll very large cohorts to more accurately estimate the relative risks of oral in relation to vaginal and rectal HIV-1 exposure. In contrast, primate model studies allow stringent control of virus dose, strain and tropism, timing, mucosal route and status of mucosal tissues. Our R5 SHIV-C/primate model system can address basic questions of mucosal permeability to a virus encoding HIV-1 env with the tropism typical of that of sexually transmitted HIV-1. As such, our data confirmed that the oral route carried the lowest risk, but the difference between oral as compared to vaginal exposure was less than 10-fold in the absence of mucosal trauma or inflammation.
Possible sites of virus entry after oral challenge and subsequent viral dissemination have been examined previously in SIV/macaque models [17, 42]. When concentrated SIV was swabbed directly onto tonsils, rapid infection ensued at this site, followed by spread to local and regional LN [42]. A subsequent study assessed initial virus target tissues and the rapidity of virus dissemination in infant/juvenile macaques upon repeated high-dose SIV challenge via buccal mucosa, gingiva and tonsils, followed by swallowing of the inoculum [17]. Sacrifice one day after this method of virus exposure revealed high SIV DNA copy numbers in gingival tissues, esophagus, submandibular and peripheral LN, and Peyer’s patches. Given the number of positive tissues, initial portal(s) of viral entry remain unclear. To test whether local inflammation enhanced transmission, our study limited R5 SHIV exposure to buccal mucosa. The increased transmission via inflamed buccal mucosa we observed is compatible with clinical observations that the presence of oral ulcers was associated with seroconversion after oral HIV exposure [40, 41]. Given the infiltration of CD4+ cells into inflamed buccal mucosa in our macaques, the increased presence of viral target cells probably accounted for enhanced SHIV-C transmission.
Several MHC class I alleles have been linked to control of chronic SIV/HIV infection. Prior studies have shown that Mamu-A*01+ Indian rhesus better controlled chronic SIVmac infection and survived longer compared to animals without this allele (reviewed in [43]). In our study, 4 out of 27 Indian macaques were Mamu-A*01+. We found no correlation between Mamu-A*01 status and susceptibility to de novo infection or viral set points. In fact, some Mamu-A*01+ animals had high viral RNA levels during acute infection. To our knowledge, no link has been established between MHC class I alleles and primate susceptibility to lentiviral acquisition. A priori, we would not expect to find any correlation, because MHC class I presentation of viral antigenic peptides can only occur after productive infection of the host has taken place.
Acute infection is associated with marked depletion of CD4+ memory T cells, primarily in mucosae in SIV-infected macaques and HIV-infected humans [44, 45]. SHIV89.6P and X4 SHIVs predominantly target/destroy naïve CD4+ T cells, leading to their rapid loss in peripheral blood [46]. In contrast, during R5 SHIV-1157ipd3N4 infection, initial declines in peripheral blood memory T cells were followed by gradual loss of absolute numbers of CD4+ T cells, a pattern described for other R5 viruses [46]. AIDS occurred in two SHIV-1157ipd3N4-infected macaques thus far. Gut CD4+ cell depletion together with the gradual T-cell depletion in blood mimic HIV disease progression in humans. Of note, another R5 SHIV, SHIVSF162P3, also gradually induced AIDS in some but not all infected macaques [47].
In summary, SHIV-1157ipd3N4 exhibits biological characteristics that parallel many aspects of HIV-1 transmission and pathogenesis in humans. This R5 SHIV-C could be a biologically relevant tool to assess mechanisms of mucosal transmission, including the role of local inflammation and coinfection with other pathogens [22], and it could also be used to assess the protective potential of microbicides or vaccines in macaques of either Indian [48] or Chinese origin against mucosal challenge.
Supplementary Material
Acknowledgements
We thank Susan Sharp for assistance in the preparation of this manuscript and Stephanie Ehnert for coordinating sample collections. This work was supported by National Institutes of Health grants P01 AI048240, R01 DE012937, R01 DE016013, R56 AI062515, and base grant RR-00165 providing support to the Yerkes National Primate Research Center. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the CDC.
Footnotes
Disclosure The authors declare no conflict of interest.
1. Baggaley RF, White RG, Boily MC. Systematic review of orogenital HIV-1 transmission probabilities. Int J Epidemiol. 2008;37:1255–65. [PMC free article] [PubMed]
2. Hladik F, Hope TJ. HIV infection of the genital mucosa in women. Curr HIV/AIDS Rep. 2009;6:20–8. [PubMed]
3. Hladik F, McElrath MJ. Setting the stage: host invasion by HIV. Nat Rev Immunol. 2008;8:447–57. [PMC free article] [PubMed]
4. Mofenson LM. Advances in the prevention of vertical transmission of human immunodeficiency virus. Semin Pediatr Infect Dis. 2003;14:295–308. [PubMed]
5. Pope M, Haase AT. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med. 2003;9:847–52. [PubMed]
6. Scarlatti G. Mother-to-child transmission of HIV-1: advances and controversies of the twentieth centuries. AIDS Rev. 2004;6:67–78. [PubMed]
7. Ruprecht RM. Mertens TE, Dias-Ferrao V, Wedel A, et al., editors. Basic Science in HIV / AIDS: An Update. Geneva: World Health Organization /UNAIDS; 1999. Oral transmission of HIV-1.
8. Winkelstein W, Jr., Lyman DM, Padian N, et al. Sexual practices and risk of infection by the human immunodeficiency virus. The San Francisco Men’s Health Study. JAMA. 1987;257:321–5. [PubMed]
9. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet. 2001;357:1149–53. [PubMed]
10. Powers KA, Poole C, Pettifor AE, Cohen MS. Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis. 2008;8:553–63. [PMC free article] [PubMed]
11. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis. 2005;191:1403–9. [PubMed]
12. Abel K, Pahar B, Van Rompay KK, et al. Rapid virus dissemination in infant macaques after oral simian immunodeficiency virus exposure in the presence of local innate immune responses. J Virol. 2006;80:6357–67. [PMC free article] [PubMed]
13. Baba TW, Koch J, Mittler ES, et al. Mucosal infection of neonatal rhesus monkeys with cell-free SIV. AIDS Res Hum Retroviruses. 1994;10:351–7. [PubMed]
14. Baba TW, Trichel AM, An L, et al. Infection and AIDS in adult macaques after nontraumatic oral exposure to cell-free SIV. Science. 1996;272:1486–9. [PubMed]
15. Marx PA, Spira AI, Gettie A, et al. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med. 1996;2:1084–9. [PubMed]
16. Miller CJ, Li Q, Abel K, et al. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol. 2005;79:9217–27. [PMC free article] [PubMed]
17. Milush JM, Kosub D, Marthas M, et al. Rapid dissemination of SIV following oral inoculation. AIDS. 2004;18:2371–80. [PubMed]
18. Trichel AM, Roberts ED, Wilson LA, Martin LN, Ruprecht RM, Murphey-Corb M. SIV/DeltaB670 transmission across oral, colonic, and vaginal mucosae in the macaque. J Med Primatol. 1997;26:3–10. [PubMed]
19. Van Rompay KK, Berardi CJ, Dillard-Telm S, et al. Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J Infect Dis. 1998;177:1247–59. [PubMed]
20. Song RJ, Chenine AL, Rasmussen RA, et al. Molecularly cloned SHIV-1157ipd3N4: a highly replication- competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env. J Virol. 2006;80:8729–38. [PMC free article] [PubMed]
21. Humbert M, Rasmussen RA, Song R, et al. SHIV-1157i and passaged progeny viruses encoding R5 HIV-1 clade C env cause AIDS in rhesus monkeys. Retrovirology. 2008;5:94. [PMC free article] [PubMed]
22. Chenine AL, Shai-Kobiler E, Steele LN, et al. Acute Schistosoma mansoni infection increases susceptibility to systemic SHIV clade C infection in rhesus macaques after mucosal virus vxposure. PLoS Negl Trop Dis. 2008;2:e265. [PMC free article] [PubMed]
23. Derdeyn CA, Decker JM, Sfakianos JN, et al. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol. 2000;74:8358–67. [PMC free article] [PubMed]
24. Hofmann-Lehmann R, Swenerton RK, Liska V, et al. Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load: comparison of one- versus two-enzyme systems. AIDS Res Hum Retroviruses. 2000;16:1247–57. [PubMed]
25. Siddappa NB, Song R, Kramer VG, et al. Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection. J Virol. 2009;83:1422–32. [PMC free article] [PubMed]
26. Yearley JH, Kanagy S, Anderson DC, et al. Tissue-specific reduction in DC-SIGN expression correlates with progression of pathogenic simian immunodeficiency virus infection. Dev Comp Immunol. 2008;32:1510–21. [PubMed]
27. Spouge JL. Statistical analysis of sparse infection data and its implications for retroviral treatment trials in primates. Proc Natl Acad Sci U S A. 1992;89:7581–5. [PubMed]
28. Bogers WM, Dubbes R, ten Haaft P, et al. Comparison of in vitro and in vivo infectivity of different clade B HIV-1 envelope chimeric simian/human immunodeficiency viruses in Macaca mulatta. Virology. 1997;236:110–7. [PubMed]
29. Chenine AL, Ferrantelli F, Hofmann-Lehmann R, Vangel MG, McClure HM, Ruprecht RM. Older rhesus macaque infants are more susceptible to oral infection with simian-human immunodeficiency virus 89.6P than neonates. J Virol. 2005;79:1333–6. [PMC free article] [PubMed]
30. Galvin SR, Cohen MS. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol. 2004;2:33–42. [PubMed]
31. Leynaert B, Downs AM, de Vincenzi I. Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection. European Study Group on Heterosexual Transmission of HIV. Am J Epidemiol. 1998;148:88–96. [PubMed]
32. Page-Shafer K, Veugelers PJ, Moss AR, Strathdee S, Kaldor JM, van Griensven GJ. Sexual risk behavior and risk factors for HIV-1 seroconversion in homosexual men participating in the Tricontinental Seroconverter Study, 1982-1994. Am J Epidemiol. 1997;146:531–42. [PubMed]
33. Royce RA, Sena A, Cates W, Jr., Cohen MS. Sexual transmission of HIV. N Engl J Med. 1997;336:1072–8. [PubMed]
34. Saracco A, Veglia F, Lazzarin A. Risk of HIV-1 transmission in heterosexual stable and random couples. The Italian Partner Study. J Biol Regul Homeost Agents. 1997;11:3–6. [PubMed]
35. Vittinghoff E, Douglas J, Judson F, McKirnan D, MacQueen K, Buchbinder SP. Percontact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol. 1999;150:306–11. [PubMed]
36. Moutsopoulos NM, Greenwell-Wild T, Wahl SM. Differential mucosal susceptibility in HIV-1 transmission and infection. Adv Dent Res. 2006;19:52–6. [PubMed]
37. Burdo TH, Marcondes MC, Lanigan CM, Penedo MC, Fox HS. Susceptibility of Chinese rhesus monkeys to SIV infection. AIDS. 2005;19:1704–6. [PubMed]
38. Ling B, Veazey RS, Luckay A, et al. SIV(mac) pathogenesis in rhesus macaques of Chinese and Indian origin compared with primary HIV infections in humans. AIDS. 2002;16:1489–96. [PubMed]
39. Katayama S, Nishizawa K, Hirano M, Yamamura S, Momose Y. Effect of polaprezinc on healing of acetic acid-induced stomatitis in hamsters. Journal of Pharmacy & Pharmaceutical Sciences: a publication of the Canadian Society for Pharmaceutical Sciences, Société Canadienne des Sciences Pharmaceutiques. 2000;3:114–7. [PubMed]
40. Faruque S, Edlin BR, McCoy CB, et al. Crack cocaine smoking and oral sores in three inner-city neighborhoods. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13:87–92. [PubMed]
41. Wallace JI, Porter J, Weiner A, Steinberg A. Oral sex, crack smoking, and HIV infection among female sex workers who do not inject drugs. Am J Public Health. 1997;87:470. [PubMed]
42. Stahl-Hennig C, Steinman RM, Tenner-Racz K, et al. Rapid infection of oral mucosal-associated lymphoid tissue with simian immunodeficiency virus. Science. 1999;285:1261–5. [PubMed]
43. Bontrop RE, Watkins DI. MHC polymorphism: AIDS susceptibility in non-human primates. Trends Immunol. 2005;26:227–33. [PubMed]
44. Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004;200:749–59. [PMC free article] [PubMed]
45. Mattapallil JJ, Smit-McBride Z, McChesney M, Dandekar S. Intestinal intraepithelial lymphocytes are primed for gamma interferon and MIP-1beta expression and display antiviral cytotoxic activity despite severe CD4(+) T-cell depletion in primary simian immunodeficiency virus infection. J Virol. 1998;72:6421–9. [PMC free article] [PubMed]
46. Nishimura Y, Brown CR, Mattapallil JJ, et al. Resting naive CD4+ T cells are massively infected and eliminated by X4-tropic simian-human immunodeficiency viruses in macaques. Proc Natl Acad Sci USA. 2005;102:8000–5. [PubMed]
47. Harouse JM, Gettie A, Eshetu T, et al. Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3) J Virol. 2001;75:1990–5. [PMC free article] [PubMed]
48. Rasmussen RA, Ong H, Song R, et al. Efficacy of a multigenic protein vaccine containing multimeric HIV gp160 against heterologous SHIV clade C challenges. AIDS. 2007;21:1841–8. [PubMed]
49. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41:1–19. [PubMed]